Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Alzamend Neuro Inc (ALZN)

Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,863
  • Shares Outstanding, K 3,890
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,950 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta -0.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/24
See More
  • Average Estimate -2.38
  • Number of Estimates 1
  • High Estimate -2.38
  • Low Estimate -2.38
  • Prior Year 4.40
  • Growth Rate Est. (year over year) -154.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2200 +2.46%
on 12/03/24
1.6900 -26.04%
on 11/05/24
-0.3950 (-24.01%)
since 11/01/24
3-Month
1.2200 +2.46%
on 12/03/24
2.5799 -51.55%
on 09/04/24
-1.1500 (-47.92%)
since 09/03/24
52-Week
1.2200 +2.46%
on 12/03/24
15.0600 -91.70%
on 08/19/24
-9.9500 (-88.84%)
since 12/01/23

Most Recent Stories

More News
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Alzamend Neuro, Inc. (NASDAQ:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease

ALZN : 1.2500 (unch)
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

October 15,

ALZN : 1.2500 (unch)
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference

October 10,

ALZN : 1.2500 (unch)
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease

ALZN : 1.2500 (unch)
New Study Reveals How Classical Music Could Revolutionize Depression Care

In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of patients...

ALZN : 1.2500 (unch)
NBIX : 125.44 (-0.36%)
TAK : 13.92 (+0.43%)
AXSM : 100.49 (+1.42%)
BIIB : 160.85 (-2.06%)
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of Next-Generation Treatment for Major Depressive Disorder

Major Depressive Disorder (MDD) was the third leading cause of global disease burden in 2008, according to the World Health Organization, with projections that it could become the leading cause by 2030....

ALZN : 1.2500 (unch)
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder

Harvard University Associate Professor, Dr. Ovidiu Andronesi MD, PhD, will be the principal investigator of the study Head-to-head study of AL001 versus a marketed lithium carbonate product will be conducted;...

ALZN : 1.2500 (unch)
Revolutionary Magnetic Therapy Could Speed Up Bipolar Treatment

New research suggests that powerful magnets could effectively treat bipolar disorder. This therapy, which is known as accelerated intermittent theta burst stimulation (iTBS), uses magnetic waves targeted...

ALZN : 1.2500 (unch)
VNDA : 4.91 (-2.58%)
ITCI : 85.31 (-0.84%)
TEVA : 17.53 (+5.29%)
ABBV : 181.50 (-0.15%)
Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder and Alzheimer’s Disease

Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide.1 Rising cases has led to an uptick in new treatments moving through the clinical...

ALZN : 1.2500 (unch)
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder

Alzamend Neuro, Inc. (Nasdaq:ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease

ALZN : 1.2500 (unch)

Business Summary

Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline...

See More

Key Turning Points

3rd Resistance Point 1.3733
2nd Resistance Point 1.3367
1st Resistance Point 1.2933
Last Price 1.2500
1st Support Level 1.2133
2nd Support Level 1.1767
3rd Support Level 1.1333

See More

52-Week High 15.0600
Fibonacci 61.8% 9.7731
Fibonacci 50% 8.1400
Fibonacci 38.2% 6.5069
Last Price 1.2500
52-Week Low 1.2200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar